Prevalence of anxiety and depression symptoms in a sample of outpatients with ATTR cardiac amyloidosis

Patients with ATTR cardiac amyloidosis (ATTR-CA) face rare disease that could negatively influence psychological well-being with consequences on the course of the disease and quality of life. However, to date, no study analyzed the prevalence of anxiety and depression in patients with ATTR-CA and which clinical and sociodemographic characteristics are linked with these psychopathological conditions. A total of 109 consecutive patients (83% males) aged 62–90 years with ATTR-CA were recruited. In order to better understand the prevalence of anxiety and depression in ATTR-CA, a control group composed by 33 individuals equaling gender, education, and age were recruited. The level of anxiety and depression was measured using the Italian version of the Hospital Anxiety and Depression Scale (HADS). Sociodemographic and clinic characteristics were registered. Almost half of patients (49%) reported a clinical level of depression or anxiety, or both. ATTR-CA patients reported higher levels of anxiety and depression than control group. Results showed that older patients with ATTR-CA, especially females, with more advanced disease could be more at risk to develop an anxious disorder. Furthermore, being a woman, and presenting with a greater severity of symptoms, would appear to be a risk factor for developing a depressive disorder. Overall, these results highlighted the high presence of anxiety and depression in ATTR-CA patients, suggesting to physicians to pay attention to the psychological well-being of ATTR-CA patients. In fact, a psychological support for patients with high level of psychopathological disease could reduce disease burden and improve quality of life in ATTR-CA population.

[1]  V. Planté-Bordeneuve,et al.  Amyloidosis from the patient perspective: the French daily impact of amyloidosis study , 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[2]  C. James,et al.  Anxiety and depression in inherited channelopathy patients with implantable cardioverter-defibrillators , 2021, Heart rhythm O2.

[3]  M. Emdin,et al.  Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis , 2021, European journal of clinical investigation.

[4]  C. Di Mario,et al.  Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany. , 2021, International journal of cardiology.

[5]  U. Eriksson,et al.  Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. , 2021, European heart journal.

[6]  A. Costa,et al.  Cognitive and mental health changes and their vulnerability factors related to COVID-19 lockdown in Italy , 2021, PloS one.

[7]  C. Di Mario,et al.  Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems. , 2020, The Canadian journal of cardiology.

[8]  P. Knapp,et al.  Frequency of anxiety after stroke: An updated systematic review and meta-analysis of observational studies , 2020, International journal of stroke : official journal of the International Stroke Society.

[9]  Peter Y. Kim,et al.  Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis , 2018, Open Heart.

[10]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[11]  W. Lenderking,et al.  Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers , 2018, Neurology and Therapy.

[12]  J. Sequeiros,et al.  Psychopathological dimensions in subjects with hereditary ATTR V30M amyloidosis and their relation with life events due to the disease , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[13]  K. Årestedt,et al.  Is the Hospital Anxiety and Depression Scale (HADS) a valid measure in a general population 65–80 years old? A psychometric evaluation study , 2017, Health and Quality of Life Outcomes.

[14]  C. Rapezzi,et al.  Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.

[15]  Carly M. Goldstein,et al.  Depression increases the risk of mortality in patients with heart failure: A meta-analysis. , 2017, Journal of psychosomatic research.

[16]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[17]  D. Seldin,et al.  Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients# , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[18]  M. Smorti,et al.  Anxiety and depression among amyloid light-chain cardiac amyloidosis patients: The role of life satisfaction , 2016, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[19]  J. Berk,et al.  Symptoms of Depression and Anxiety Assessed By the SF-36 Questionnaire in Patients with AL Amyloidosis , 2015 .

[20]  M. Costantini,et al.  A confirmatory bifactor analysis of the hospital anxiety and depression scale in an Italian community sample , 2014, Health and Quality of Life Outcomes.

[21]  M. Smorti,et al.  Depression and cardiac symptoms among AL amyloidosis patients: the mediating role of coping strategies , 2014, Psychology, health & medicine.

[22]  F. Salvi,et al.  Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. , 2013, European heart journal.

[23]  M. Smorti,et al.  Anxiety and depression among AL amyloidosis patients: the role of cardiac symptoms , 2012, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[24]  David R. Williams,et al.  Mental disorders among persons with heart disease - results from World Mental Health surveys. , 2008, General hospital psychiatry.

[25]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.